secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001193125-23-277914
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Gene Therapies stockholders approve doubling authorized common stock to 400M shares
--------------------------------------------------------------------------------

- Special meeting on Nov 15, 2023: 72.16% of shares represented; amendment passed with 133,386,292 votes for.
- Authorized shares increased from 200,000,000 to 400,000,000 via Certificate of Amendment filed with Delaware.
- Only 1,370,285 votes against and 157,132 abstained out of 134,913,709 shares voted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523277914/0001193125-23-277914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523277914/d941656d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-277914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer